Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06016634 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Sep 2027
    • Study completion moved earlier from Dec 31, 2027 to Dec 2027
    • Secondary endpoints: 2 to 3
    v11
  2. Start date changed from estimate of Feb 9, 2026 to Mar 9, 2026v10
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2025 to Feb 9, 2026
    • Site details revised
    v9
  4. Start date: Sep 2025 to Dec 2025v8
  5. Primary completion date: Dec 2025 to Dec 31, 2026v7 Show 4 more changesShow less
    • Trial status: Recruiting to Not Yet Recruiting
    • Enrollment target: 24 to 30
    • Study completion date: Jun 2026 to Dec 31, 2027
    • Site details revised
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Sep 2024 to Sep 2025v6
  2. Trial status: Not Yet Recruiting to Recruitingv5 Show 5 more changesShow less
    • Primary completion date: Feb 2025 to Dec 2025
    • Start date: Mar 2024 to Sep 2024
    • Study sites: 0 to 1
    • Study completion date: Jul 2025 to Jun 2026
    • Study description expanded, about 5 words
  3. Start date: Jan 2024 to Mar 2024v4 Show 4 more changesShow less
    • Primary completion date: Dec 2024 to Feb 2025
    • Study completion date: Jun 2025 to Jul 2025
    • Study description shortened, about 1 word
    • Study title shortened, about 1 word
  4. Start date: Oct 2023 to Jan 2024v3
  5. Start date: Sep 2023 to Oct 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Trial Details
NCT Number NCT06016634
Lead Sponsor University of California, Davis
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Doris Duke Charitable Foundation
Conditions
(from sponsor)		 Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
Related terms Anemia, Sickle Cell, Legg-Calve-Perthes Disease, Osteonecrosis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov